2 Dividend Kings For A Potentially Comfortable Retirement

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. Still, Wall Street expects the New Bru...

JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson...

I recently purchased 15 shares of Johnson & Johnson, and discuss how it fits into my dividend cash machine. I emphasize the importance of dividend cash and compounding in building wealth over time....

Companies that sell everyday products you know well may be the key to your future wealth. They may offer you earnings growth over time and annual dividend payments.

Investing in companies that have raised their payouts annually for six decades or more has paid off over the long haul.

Johnson & Johnson (JNJ) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would purchase the biotechnology firm to add to its cancer-fighting drug portfolio.

Johnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm's marketing of its talcum powder, according to Bloomberg, follow...

Johnson & Johnson has tentatively agreed to pay about $700 million to resolve an investigation by over 40 U.S. states into claims it wrongfully marketed its talc-based baby powder, Bloomberg News r...

Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash merger transaction for a total equity valu...

Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.

Johnson & Johnson's leading product, Stelara, is nearing the end of its exclusivity, which will likely slow down the growth of earnings per share. JNJ prioritizes growth in investments, with a focu...

The Dow Jones Industrial Average is up 3.64% over the past month, and technical indicators show that it could extend much further. If last year's repeat of the ‘Majestic Seven' leading the broader ...